TDO2 Antibody (998604) [Alexa Fluor™ Plus 405]

• Reactivity: Hu
• Clone: 998604
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 405

TDO2 Antibody (998604) [Alexa Fluor™ Plus 405] Summary

• Specificity: Detects human TDO2 in direct ELISAs.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TDO2 Antibody (998604) [Alexa Fluor™ Plus 405]

• chky
• TDO
• TDO2
• TDOTO
• TO
• TPH2EC 1.13.11.11
• TRPO
• TRPOtryptophanase
• Tryptamin 2,3-dioxygenase
• tryptophan 2,3-dioxygenase
• Tryptophan Oxygenase
• Tryptophan Pyrrolase
• Tryptophanase

Background

Tryptophan 2,3-dioxygenase (TDO2), a heme-containing cytosolic dioxygenase, forms a homo-tetrameric active molecule of approximately 190 kDa composed of 48 kDa monomers (1, 2). Human TDO2 shares 89% aa sequence identity with mouse TDO2. TDO2 is one of three proteins capable of catalyzing the first and rate‑limiting step of the L-kynurenine pathway (KP): oxidative cleavage of the essential amino acid L-tryptophan to form N‑formyl‑kynurenine (3). TDO2 is a cytosolic protein typically localized to the liver and brain, unlike the more ubiquitously expressed indoleamine 2,3-dioxygenase (IDO), yet it is responsible for ~90% of the primary route of catabolism of tryptophan through the KP (3). TDO2 is upregulated in extrahepatic tumors (4-6) and is consequently a target in cancer immunotherapy (7). TDO2 is a therapeutic target in brain disease such as schizophrenia, Alzheimers disease, multiple sclerosis and glioma (8-11) due to its role in the regulation of levels of critical biologically active downstream KP metabolites (3). Polymorphisms in the TDO2 gene have been implicated for a role in behavioural responses and autism (12,13).

1. Lewis-Ballester, A. et al. (2016) Sci. Rep. 6:35169.
2. Rafice, S.A. et al. (2009) Biochem. Soc. Trans. 37:408.
3. Badawy, A. (2017) Int J. Tryptophan Res. 10:1.
4. Pilotte, L. et al. (2012) Proc. Natl. Acad. Sci. U.S.A. 109:2497.
5. D'Amato, N.C. et al. (2015) Cancer Res. 75:4651.
6. Yu, C.P et al. (2017) Med. Oncol. 34:73.
7. Platten, et al. (2015) Front. Immunol. 5:673.
8. Breda, C. et al. (2016) Proc. Natl. Acad. Sci. U.S.A. 113:5435.
9. Yu, C.P. et al. (2016) Metab. Brain Dis. 31:737.
10. Lanz. T.V. et al. (2017) Sci. Rep. 7:41271.
11. Reus, G.Z. et al. (2018) Prog. Neuropsychopharmacol. Biol. Psychiatry 81:55.
12. Soichot, M. et al. (2013) Alcohol Alcohol 48:415.
13. Nabi, R. et al. (2004) Am. J. Med. Genet. B. Neuropsychiatr. Genet. 125B:63.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.